Viatris Reports Strong Q3 2025 Financial Results

Viatris ( (VTRS) ) has shared an update.

On November 6, 2025, Viatris reported strong financial results for the third quarter of 2025, with total revenues aligning with expectations. The company made significant progress in its late-stage pipeline, including an NDA submission for a low-dose estrogen patch, and acquired Aculys Pharma, enhancing its market presence in Japan and the Asia-Pacific region. Viatris returned over $920 million to shareholders, raised its financial guidance for 2025, and is preparing for strategic actions to ensure sustainable growth beyond 2025.

The most recent analyst rating on (VTRS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page.

Spark’s Take on VTRS Stock

According to Spark, TipRanks’ AI Analyst, VTRS is a Neutral.

Viatris’ overall stock score is primarily influenced by its financial performance challenges, including declining revenues and high leverage. Technical analysis suggests a neutral market sentiment, while valuation is hindered by negative earnings despite a high dividend yield. The earnings call provides some optimism with strategic initiatives and pipeline advancements, but ongoing regional challenges and operational issues remain significant concerns.

To see Spark’s full report on VTRS stock, click here.

More about Viatris

Viatris Inc. operates in the pharmaceutical industry, focusing on providing access to medicines, sustainable operations, and innovative solutions. The company offers a wide range of products, including generics, brands, and over-the-counter medicines, with a strong presence in developed, emerging, and Asia-Pacific markets.

Average Trading Volume: 9,592,452

Technical Sentiment Signal: Buy

Current Market Cap: $12.11B

Find detailed analytics on VTRS stock on TipRanks’ Stock Analysis page.